Work

50378 Clinical efficacy of TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, is associated with modulation of disease and TYK2 pathway biomarkers in patients with moderate-to-severe psoriasis

Year: 2024

Type: article

Source: Journal of the American Academy of Dermatology

DOI: 10.1016/j.jaad.2024.07.632

Authors: James G. Krueger, Sandra Garcet, Jie Cheng, Sachin Kumar, Jessamyn Blau, Yiwei Zhao, Wenwen Zhang, Vinayagam Arunachalam, Graham A. Heap, Paresh Thakker, Amit Choudhury

Institutions: Rockefeller University, Takeda (United States)

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4402104113

FWCI: 0.336

Cites:

Cited by: 2

Related to: 10